Publications
Detailed Information
BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Hye-young | - |
dc.contributor.author | Noh, Hayeon | - |
dc.contributor.author | Choi, Soo Young | - |
dc.contributor.author | Lee, Sung-Eun | - |
dc.contributor.author | Kim, Soo-Hyun | - |
dc.contributor.author | Kee, Kyung-Mi | - |
dc.contributor.author | Yoo, Hea-Lyun | - |
dc.contributor.author | Lee, Mi-young | - |
dc.contributor.author | Kang, Ki-Hoon | - |
dc.contributor.author | Suh, Ji-Hyung | - |
dc.contributor.author | Yang, Seon-young | - |
dc.contributor.author | Jang, Eun-Jung | - |
dc.contributor.author | Lee, Jangik, I | - |
dc.contributor.author | Kim, Dong-Wook | - |
dc.creator | LEE JANGIK IKE | - |
dc.date.accessioned | 2019-04-25T01:52:26Z | - |
dc.date.available | 2020-04-05T01:52:26Z | - |
dc.date.created | 2018-12-21 | - |
dc.date.issued | 2018-10 | - |
dc.identifier.citation | Cancer Medicine, Vol.7 No.10, pp.5107-5117 | - |
dc.identifier.issn | 2045-7634 | - |
dc.identifier.uri | https://hdl.handle.net/10371/149774 | - |
dc.description.abstract | The present study aimed to assess the clinical impact of BCR-ABL1 transcript levels determined at an earlier time point than the 3-month early molecular response (EMR) in chronic-phase chronic myeloid leukemia (CML-CP) patients. BCR-ABL1 transcript levels of CML-CP patients (n = 258; median age, 43 [range, 18-81] years) treated with various tyrosine kinase inhibitors (TKIs) were determined at 4 weeks (28 +/- 3 days) and at every 3 months of treatment initiation. At 4 weeks, receiver operating characteristic curves revealed that cutoff values of BCR-ABL1 transcripts for achieving major molecular responses (MMRs) by 12 and 60 months were 40.89% and 39.16%, respectively (95% CI, 0.658-0.772 and 95% CI, 0.643-0.758; P < 0.0001). With 40% of BCR-ABL1 transcripts at 4 weeks (very early MR; VEMR), patients with VEMR achieved higher 3-month EMR and 4-week VEMR significantly associated with higher cumulative incidences of 5-year MMR (89.1% vs 72.3%; P < 0.001) and 5-year deep molecular response (DMR) (56.5% vs 29.4%; P = 0.001). Furthermore, event-free survival (EFS)-a (93.0% vs 84.8%; P = 0.068) and EFS-b (71.1% vs 57.9%; P = 0.061) by 5 years were also marginally significant. VEMR and 3-month EMR were achieved in 89 patients, with significantly superior outcomes. In multivariate analyses, lower leukocyte count (P = 0.008) and frontline second-generation TKI therapy size (P < 0.001) were significantly associated with VEMR achievement, but not baseline BCR-ABL1 level and CML duration. In conclusion, the 4-week BCR-ABL1 transcript levels including VEMR could be important to predict long-term outcomes and may provide additional information about innate intrinsic sensitivity to CML among individuals. | - |
dc.language | 영어 | - |
dc.language.iso | en | en |
dc.publisher | John Wiley and Sons Ltd | - |
dc.title | BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors | - |
dc.type | Article | - |
dc.identifier.doi | 10.1002/cam4.1753 | - |
dc.citation.journaltitle | Cancer Medicine | - |
dc.identifier.wosid | 000448053500024 | - |
dc.identifier.scopusid | 2-s2.0-85052808749 | - |
dc.description.srnd | OAIID:RECH_ACHV_DSTSH_NO:T201812193 | - |
dc.description.srnd | RECH_ACHV_FG:RR00200001 | - |
dc.description.srnd | ADJUST_YN: | - |
dc.description.srnd | EMP_ID:A080110 | - |
dc.description.srnd | CITE_RATE:3.202 | - |
dc.description.srnd | FILENAME:20180801_BCR-ABL1TranscriptLevelsAt_SongHY&LeeJI&KimDW_CancerMed2018(7-10)5107.pdf | - |
dc.description.srnd | DEPT_NM:약학과 | - |
dc.description.srnd | EMAIL:jangik.lee@snu.ac.kr | - |
dc.description.srnd | SCOPUS_YN:Y | - |
dc.description.srnd | FILEURL:https://srnd.snu.ac.kr/eXrepEIR/fws/file/7497b374-117f-4046-9d3f-c56713de5cdb/link | - |
dc.citation.endpage | 5117 | - |
dc.citation.number | 10 | - |
dc.citation.startpage | 5107 | - |
dc.citation.volume | 7 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Lee, Jangik, I | - |
dc.identifier.srnd | T201812193 | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | EARLY MOLECULAR RESPONSE | - |
dc.subject.keywordPlus | CML PATIENTS | - |
dc.subject.keywordPlus | IMATINIB | - |
dc.subject.keywordPlus | ACHIEVEMENT | - |
dc.subject.keywordPlus | DASATINIB | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | INTERFERON | - |
dc.subject.keywordPlus | VELOCITY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | chronic myeloid leukemia | - |
dc.subject.keywordAuthor | early molecular response | - |
dc.subject.keywordAuthor | molecular response | - |
dc.subject.keywordAuthor | predictor | - |
dc.subject.keywordAuthor | tyrosine kinase inhibitor | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.